Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by mutations in either of two genes, TSC1 or TSC2, resulting in the constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1). mTOR inhibitors are now considered the treatment of choice for TSC disease. A major pathological feature of TSC is the development of subependymal giant cell astrocytomas (SEGAs) in the brain. Nowadays, it is thought that SEGAs could be a consequence of aberrant aggregation and migration of neural stem/progenitor cells (NSPCs). Therefore, reactivation of cell migration of NSPCs might be the crucial step for the treatment of patients. In order to identify potential in vitro targets activating migration, we generated Tsc1-deficient NSPCs. These cells summarize most of the biochemical and morphological characteristics of TSC neural cells, such as the mTORC1 activation, the formation of abnormally enlarged astrocytes-like cells, the reduction of autophagy flux and the impairment of cell migration. Moreover, nuclear translocation, namely activation of the transcription factor EB (TFEB) was markedly impaired. Herein, we show that compounds such as everolimus, ionomycin and curcumin, which directly or indirectly stimulate TFEB nuclear translocation, restore Tsc1-deficient NSPC migration. Our data suggest that reduction of TFEB activation, caused by mTORC1 hyperactivation, contributes to the migration deficit characterizing Tsc1-deficient NSPCs. The present work highlights TFEB as a druggable protein target for SEGAs therapy, which can be additionally or alternatively exploited for the mTORC1-directed inhibitory approach.
Introduction
Tuberous sclerosis complex (TSC) is a multisystem and autosomal dominant disorder characterized by the development of benign tumours in different tissue. TSC is caused by inactivating mutations in either TSC1 (1), or TSC2 (2) genes, encoding for hamartin or tuberin protein, respectively. In the cell, TSC1/TSC2 complex inhibits the mammalian target of rapamycin complex 1 (mTORC1) activity. Therefore, the symptoms of TSC are related to mTORC1 hyperactivation (3) . TSC patients commonly present masses known as cortical tubers, subependymal nodules (SENs) and subependymal giant cell astrocytomas (SEGAs) in the central nervous system (CNS) (4, 5) . SENs and SEGAs might arise after loss of heterozygosity, caused by somatic mutation, in either embryonic neural stem cells (NSCs) or neural stem/ progenitor cells (NSPCs) (6) . Deletion of TSC1 function in NSPCs can lead to development of SEN and SEGA-like structures caused by impaired aggregation and migration of the subventricular zone (SVZ) NSPCs (7) .
In the last few year, the US Food and Drug Administration has approved everolimus, a rapamycin-derivative mTOR inhibitor, for the treatment of unresectable symptomatic SEGAs and other TSC manifestations such as renal angiomyolipoma, lymphangioleiomyomatosis and, most recently, epilepsy (8) (9) (10) (11) (12) (13) (14) . Treatment with everolimus is associated with a significant risk of adverse events, including non-infectious pneumonitis, infections, oral ulceration, acne, amenorrhoea, disturbed wound healing, and metabolic events (e.g., hyperglycemia, dyslipidemia) (12, 15) . However, clinical experiences with everolimus in patients with TSC indicate that long-term everolimus therapy is generally well tolerated, with the major part of the adverse effects being mild to moderate. (16, 17) .
Cell migration is a fundamental process for the normal development of all mammalian organs including the CNS (18) . In the adult rodent forebrain this process remains active and occurs along the rostral migratory stream where neuroblasts, generated from NSPCs, can migrate to the olfactory bulbs (19, 20) . Cell migration is a highly integrated, multi-step process under the tight control of different signalling events and its alteration could lead to different abnormalities, such as tumours formation. The endosomal-lysosomal compartment is involved in the transport and release of lysosomal hydrolases in the extracellular milieu and plays a role in tumour growth and cell invasion (21) . Moreover, early as well as late endosomes play a fundamental role in the transport, both on-going and out-going, of cell surface protein, such as integrins, involved in the local regulation of each step of cell migration process (22) .
In 2009, the Ballabio group brought to light a gene network regulating lysosomal biogenesis and function. At its centre the master gene regulator, transcription factor EB (TFEB), recognizes and binds E-box sequences (5'-CANNTG-3') which are present in most of the lysosomal genes. Moreover, TFEB was also found to modulate the expression of genes involved in processes such as lysosomal acidification, exocytosis and endocytosis (21, 23) . TFEB nuclear translocation is mainly controlled by its phosphorylation status which depends on two major players, mTORC1 and the phosphatase calcineurin (24) .
In the present work, we generated a TSC-cell model by isolating NSPCs from the brain SVZ of six-week-old Tsc1 tm1Djk/J mice.
The deletion of both Tsc1 alleles was performed by transient transfection of NSPCs with a Cre recombinase expression plasmid. The TSC-cell model was used to study the molecular mechanism involved in the migration defect of Tsc1-deficient NSPCs. The data reported herein show for the first time that the migration deficit observed in Tsc1-deficient NSPCs, actually depends on the state of TFEB activation. Treatments that promote TFEB nuclear translocation, such as curcumin administration, restore Tsc1-deficient NSPCs migration independently of mTORC1.
Results

Generation of Tsc1-deficient adult neural stem progenitor cells as a CNS-derived TSC cell model
Aiming to investigate potential therapeutic targets capable of reactivating migration in Tsc1-deficient NSPCs, we isolated NSPCs from the brain SVZ of six-week-old Tsc1 c conditional mice, which possess loxP sites flanking exons 17 and 18 of the Tsc1 allele (Fig. 1C) . Primary neurospheres, which expressed both nestin and GFAP neural stem cell markers (Fig. 1A) , were singularly recovered to obtain single neurosphere culture (Tsc1 c NSPCs). Nucleofection of Tsc1 c NSPCs was performed by using a GFP.Cre plasmid expressing GFP and Cre recombinase, which was transiently expressed, as showed in Figure 1B , to delete Tsc1 allele and generate Tsc1 ko allele (Fig. 1C) .
Transiently GFP-expressing neurospheres were singularly recovered and Tsc1 allele deletion was evaluated by PCR genomic DNA analysis (Fig. 1D) . Lastly, the lack of hamartin protein expression in Tsc1-deficient (Tsc1 ko ) NSPCs was confirmed by immunoblot analysis (Fig. 1E ).
Tsc1-deficient NSPCs show an increased proliferative rate and abnormally enlarged astrocyte-like morphology showed the formation of neurospheres similar to Tsc1 c . However, differences in the neurospheres' morphology began to appear on the second day of culture. Tsc1 ko neurospheres released peripheral cells in the medium, showing a high tendency to attach to the flask surface, and their morphology was not as spherical as that of Tsc1 c neurospheres ( Fig. 2A) .
Nevertheless, Tsc1 ko NSPCs showed an increase in proliferative rate, evaluated by using trypan blue assay (Fig. 2B) . Finally, the Tsc1 ko NSPCs size was greater than control cells (Fig. 2B ). When seeded in matrigel pre-coated wells, in the presence of both b-FGF2 and EGF for 24 h, Tsc1 ko NSPCs appeared more differentiated than Tsc1 c , as shown in Figure 2C . This result was confirmed by immunofluorescence analysis performed by using either nestin or GFAP antibody, which revealed the presence of many abnormally enlarged GFAP-positive cells in Tsc1 ko culture ( Fig. 2D and E) . Likewise, immunoblot analysis confirmed the increased levels of GFAP protein (Fig. 2F) . Moreover, enhanced metabolic activity of Tsc1 ko NSPCs was attested by measuring the pH of the culture medium, which was significantly decreased in Tsc1 ko when compared to Tsc1 c cultures (Fig. 2G ).
Tsc1-deficient NSPCs show aberrant aggregation after differentiation and maturation Immunofluorescence analysis, using fluorescent phalloidin, highlighted Tsc1 ko NSPCs aggregation and fusion ( Fig. 3B) , resulting, as expected, in a reduction of Tsc1 ko cell number (Fig. 3C ).
Tsc1-deficient NSPCs show mTORC1 hyperactivation, impaired autophagy flux and reduced TFEB nuclear translocation
To investigate the effects of Tsc1 deletion on growth and proliferation in our cell model, we evaluated the mTORC1 activity by analysing the phosphorylation level of its substrates, p70S6K and 4E-BP1. Tsc1 ko NSPCs showed a marked increase in phosphop70S6K(T389), and phospho-4E-BP1(T37/46) ( Fig. 4A) indicating, as expected, that mTORC1 was activated. Data were confirmed by the increase in phospho-S6 ribosomal protein (S235/236), which is known to be a p70S6K target (Fig. 4B) . By treating NSPCs with everolimus, a drug already used for TSC therapy, mTORC1 hyperactivation was abolished and the phosphorylation levels of both p70S6K and 4E-BP1 in Tsc1 ko NSPCs were restored (Fig. 4A ).
Another signalling pathway controlled by mTORC1 is autophagy. It is known that mTORC1 activation inhibits autophagy. Therefore, we measured the conversion of LC3B-I to LC3B-II via immunoblotting. As shown in Figure 4A , the ratio between the two isoforms was lower in Tsc1
ko NSPCs compared to Tsc1 c , which highlighted a reduction in autophagosome formation. Our results demonstrate that Tsc1 ko NSPCs have a reduced autophagy as a consequence of mTORC1 activation. It has been shown that mTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of the transcription factor EB (TFEB). In particular, mTOR-dependent phosphorylation of TFEB results in retention of the transcription factor in the cytoplasm where it cannot promote gene transcription. In order to confirm that the reduced autophagy observed in TSC1 ko NSPCs was linked to inhibition of TFEB nuclear translocation, we analysed the cytosolic and nuclear fractions in both Tsc1 ko and Tsc1 c NSPCs. As shown in Figure 4B , the amount of TFEB in the nuclear fraction of Tsc1 ko NSPCs was significantly lower than in Tsc1 c cells, indicating that the reduced autophagy observed in TSC1 ko cells is dependent on mTORC1 activation (Fig. 4B ).
TFEB nuclear translocation restores Tsc1-deficient NSPC migration
Unlike to mTORC1, TFEB nuclear translocation is promoted by intracellular calcium release which controls the activities of the phosphatase calcineurin (25) . For this reason, we used two different compounds, everolimus, an mTORC1 inhibitor, and ionomycin, an ionophore used to increase intracellular calcium. Both are known (25, 26) to be able to promote TFEB nuclear translocation. We then assessed their effects on cell migration. Moreover, we also used curcumin, which has been demonstrated to activate autophagy by both promoting the inhibition of mTORC1 and directly binding TFEB, promoting its nuclear translocation (27) . As reported in Figure 5a , both everolimus and ionomycin treatment restored the nuclear TFEB level in Tsc1 ko NSPCs by inhibiting mTORC1. Differently, as shown in the same figure, TFEB nuclear translocation defect was re-established by using both ionomycin and tacrolimus, a calcineurin inhibitor. Eventually, Tsc1 ko NSPCs were also treated with curcumin, which rescued such TFEB nuclear translocation as everolimus and ionomycin (Fig. 5A) . A migration assay was performed to evaluate this aspect in our Tsc1 ko cell model. Neurospheres of about 100-150 lm in diameter were seeded in matrigel pre-coated wells. Cell migration was quantified at 2 and 24 h post-adhesion. As shown in Figure 5B and C, Tsc1 ko NSPCs displayed a significant reduction in cell migration.
The migration defect was not due to the increased cell proliferation of Tsc1 c NSPCs compared to Tsc1 ko as determined by cell viability assay (data not shown). Neurosphere migration was completely restored not only by treating Tsc1 ko NSPCs for 24 h with everolimus, but also when ionomycin was used. Finally, cell migration was also rescued by using curcumin (Fig. 5B) . The correction of the Tsc1 ko NSPC migration defect was inhibited by treatment with ionomycin and tacrolimus together (Fig. 5B ). Taken together, these results strongly suggest that, in Tsc1 ko NSPCs, cell migration is dependent on TFEB nuclear translocation.
Curcumin restores NSPC migration without effects on mTORC1 activity
The data reported so far showed that all the compounds we used, which affect TFEB nuclear translocation, restore Tsc1 ko NSPC migration. Because everolimus exerts its effects on TFEB via mTORC1 and ionomycin through calcineurin, we wondered which of the two mechanisms were responsible for the curcumin effects on cell migration. The dose-dependency of curcumin treatment was first determined by a neurosphere migration assay. As shown in Figure 6A , curcumin significantly restored the migration of Tsc1 ko NSPCs up to 93.1 6 8.7 (P < 0,01) and 101.9 6 8.2% (P < 0.001) at concentration of 0.5 and 1 lM respectively. We went on performing immunoblot analysis of the Akt-mTORC1-p70S6K signalling pathway by determining the phosphorylation levels of the main kinases. As showed in Figure 6B , curcumin treatment reduced phospho-Akt(S473) and phospho-p70S6K(T389) levels in Tsc1 c NSPCs indicating the suppression of the Akt-mTORC1 pathway. Differently, the same treatment on Tsc1 ko NSPCs reduced phospho-Akt(S473) but failed to modify phospho-p70S6K(T389) level. These results indicate that mTORC1 activity is not involved in the curcumin-mediated effect on Tsc1 ko NSPCs, confirming that reactivation of cell migration, in our cell model, can be achieved through an mTORC1 independent, TFEB-mediated pathway (Fig. 6B) .
Discussion
In the present work, we generated Tsc1-deficient NSPCs, as a CNS-derived TSC cell model, aiming to study the molecular mechanisms driving the development of subependymal nodules (SENs) and subependymal giant cell astrocytomas (SEGAs). These characteristic lesions of TSC brain originate from the uncontrolled proliferation of Tsc1-deficient embryonic VZ/SVZ cells (28) and from the aberrant aggregation and migration of postnatal SVZ NSPCs (7). Therefore, we thought that postnatal Tsc1-deficient SVZ NSPCs could be a suitable model to study neural migration in this disease. Consequently, we isolated NSPCs from six-week-old conditional mice and Tsc1 deletion was performed in clonal cells by the transient expression of Cre recombinase. This allowed us to obtain Tsc1-deficient NSPCs and the appropriate cell control. The Tsc1-deficient NSPCs obtained summarized many features of the cells found in SEGA tumours. They showed i) hyperactivation of the mTORC1 signalling pathway, as confirmed by increased levels of both phospho-p70S6K(T389) and phospho-4E-BP1(T37/46); ii) the formation of abnormally enlarged astrocyte-like cells, characterized by strong immunoreactivity to astroglial cell marker GFAP; iii) reduction of autophagosome formation as attested by a decreased ratio between LC3B-II and LC3B-I and iv) impaired migration abilities.
In Tsc1-deficient NSPCs, the hyperactivation of mTORC1 and the autophagy dysfunction led us to investigate the nuclear levels of transcription factor EB (TFEB). TFEB is a master gene, which promotes lysosomal biogenesis by regulating both the expression of lysosomal proteins and lysosomal acidification (29) . Recently, it has been demonstrated that over-expression of TFEB is associated with an increase in cell migration and poor prognosis in non-small cell lung cancer. Silencing of TFEB with siRNAs in cancer cell lines did not affect proliferation but caused a reduction in cell migration (30) . In addition, TFEB overexpression has been shown to reactivate autophagy and restore radial migration in new-born neurons where those processes were impaired (31) . It is now well established that increased lysosomal enzymatic activity and secretion of the hydrolases into the extracellular space promotes tumour growth and migration, angiogenesis, and metastasis (32) . Moreover, the role of late endosomes and lysosomes in transport of specific proteins to regulate cell migration is clearly emerging (33) .
We showed that Tsc1-deficient NSPCs exhibited both reduced nuclear levels of TFEB and migration deficit. We correlated these alterations by demonstrating that TFEB activation restored their migration abilities. To promote TFEB activation we used both everolimus and ionomycin and evaluated their effects on migration of Tsc1-deficient NSPCs. Both everolimus and ionomycin affect TFEB translocation indirectly by inhibiting mTORC1 or activating calcineurin, respectively. To demonstrate that ionomycin restored cell migration by activating calcineurin-mediated TFEB dephosphorilation, the calcineurin inhibitor tacrolimus was used, which specifically abolished the effects of the ionophore drug. In addition, we used curcumin because of its direct TFEB activation (27) . In our cell model, curcumin promoted both TFEB nuclear translocation and a dose dependent restoration of cell migration. Curcumin treatment did not reduce the mTORC1 activity as indicated by the phosphorylation levels of p-70S6K(T389), which were unchanged in curcumin-treated Tsc1-deficient NSPCs. This result confirmed that restoration of Tsc1-deficient NSPC migration was obtained by an mTORC1-independent pathway.
Studies exploring new treatments for TSC disease are mainly focused on mTOR inhibition in light of the role that TSC1 and TSC1 tumour suppressor genes play on its regulation. Acting on the main tumour effector (mTORC1), everolimus is the main example of this strategy being effective in the treatment of TSC related abnormalities and in particular for the reduction of the size of SEGAs. Nevertheless, everolimus does not eliminate SEGA tumours and long-lasting treatment with it might influence the quality of life (34) . Therefore, novel approaches for the treatment of TSC disease aiming to the restore NSPC migration could result in the improvement of SEGA therapy. Our results strengthen the hypothesis that there is a link between TFEB and cell migration, and for the first time suggest that the migration deficit characterizing Tsc1-deficient NSPCs could be restored by using an mTOR independent approach. In conclusion, the present work provides the background for the exploration of different therapeutic targets which can be alternative or additional to mTORC1-directed inhibitory therapy.
Materials and Methods
Mice
All the experiments were conducted in conformity with the European Communities Council Directive of November 1986(86/ 609/ECC), in accordance with a protocol approved by the Animal Care and Use Committee at the Regina Elena National Cancer Institute and every effort was made to minimize animal suffering. Tsc1 tm1Djk /J conditional mice were purchased from Jackson Laboratory (https://www.jax.org/strain/005680; date last accessed June 14, 2017).
Isolation of NSPCs from Tsc1
tm1Djk /J mice NSPCs were isolated from the brain SVZ of six-week-old Tsc1 everolimus (Ev, 50 nM) or not (veh). The hamartin level was normalized over b-actin. P-p70S6K and P-4EBP1 were normalized over total p70S6K and 4E-BP1, respectively. LC3B-II was normalized over LC3B-I. Values are the mean 6 SEM of five independent experiments. ## P < 0.01, Tsc1 ko vs Tsc1 c ; ***P < 0.001, **P < 0.01, *P < 0.05; Tsc1 ko Ev vs regions were removed from the brain using a stereomicroscope and minced tissue was dissected by using a digestion solution containing 0.94 mg/ml papain (Worthington Biochem. Corp.), 0.18 mg/ml cystein (Sigma-Aldrich), 20 U/ml DNAse (Roche) and 0.18 mg/ml EDTA for 30 min at 37 C. The reaction was stopped by adding complete NeuroCult 
Differentiation of neural stem progenitor cells
NSPCs differentiation of both Tsc1 c and Tsc1 ko cells was performed culturing cells in pre-coated matrigel six-well plates, according to the manufacturer's procedure (Matrix growth factor reduced; Corning). NSPCs were incubated in NeuroCult medium containing both 40 ng/ml b-FGF2 and EGF for 24 h. After that period, the cells were maintained in 10 ng/ml b-FGF2 for an additional 3 days and then switched to DMEM/F12 medium containing 2% FBS.
Drugs and cell treatments
The following drugs were used: everolimus (Ev; 50 nM, or otherwise indicated) from Selleckchem; curcumin (Cur; 1 mM) from Sigma-Aldrich; ionomycin (Io; 1 mM) from Sigma-Aldrich and tacrolimus (FK-506; 5 mM from Sigma-Aldrich).
Immunoblot analysis
Total cell lysate was prepared by solubilisation in TNE buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA and 0.5% (v/v) Triton X-100) containing protease and phosphatase cocktail inhibitors (Sigma-Aldrich). After 30 min of incubation at 4 C, the samples were centrifuged at 16,000x g for 15 min at 4 C and protein concentration was measured in the supernatant by Bradford assay. Nuclear/cytosolic fractions were isolated as previously described (36) . After SDS-PAGE, the proteins were transferred to PVDF membranes (Biorad), which were blocked in TBS (50 mM Tris-HCl, 150 mM NaCl, pH 7. (1:1000, Cell Signaling), rabbit anti-p70S6K (1:1000, Cell Signaling), rabbit anti-phospho-4E-BP1(T37/46) (1:1000, Cell Signaling), rabbit anti-4E-BP1 (1:1000, Cell Signaling), rabbit anti-phosphomTOR(S2448) (1:1000, Cell Signaling), rabbit anti-mTOR (1:1000, Cell Signaling), mouse anti-actin (1:10000, Sigma-Aldrich), rabbit anti-TFEB (1:1000, Abcam), rabbit anti-H3 (1:10000, Millipore), rabbit anti-LC3B (1:1000, Cell Signaling). After being washed, the blots were incubated with secondary antibodies anti-mouse IgG (GE Healthcare), anti-rabbit IgG (GE Healthcare) or anti-goat IgG HRPconjugated (Sigma-Aldrich). They were then developed by ECL detection system (GE Healthcare). Densitometric quantification was performed by using ImageJ software (NIH).
Immunofluorescence
NSPCs were plated on matrigel pre-coated 12 mm round glass coverslips at a concentration of 15000 cells/cm 2 V R 594 (Thermo Fisher Scientific), for 1 h in antibody solution and then mounted on glass slides using Vectashield with DAPI (Vector Laboratories Inc). Fluorescence microscopy analysis was performed using a Nikon TE2000 microscope (Nikon Instruments S.p.A, Florence, Italy) through a 60x oil immersion objective. Image processing was performed using Adobe-Photoshop CS software (Adobe Systems Incorporated). Fluorescence intensity (FI) analysis was performed by using ImageJ software (NIH).
Neurosphere migration assay
Neurosphere migration was assessed as reported by Mobley AK and Mccarty JH (37) , with some modification. Briefly, single neurospheres, both Tsc1 c and Tsc1 ko , were allowed to adhere onto matrigel pre-coated 6-well plates. The migration ability was evaluated by capturing images at 2 and 24 h post-adhesion using a Nikon TE2000 microscope. Total area of each neurosphere at 2 and 24 h was then calculated drawing a line around the migrating cells and then quantifying the area using ImageJ software. Neurosphere migration was then expressed as the difference between the area at 2 and 24 h.
Statistical analysis
All data were expressed as mean 6 SEM. Statistical differences were evaluated using unpaired Student's t test. The threshold for statistical significance was set at P < 0.05.
